Loading...

Arrowhead Pharmaceuticals

DB:HDP1
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
HDP1
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The last earnings update was 8 days ago. More info.


Add to Portfolio Compare Print
  • Arrowhead Pharmaceuticals has significant price volatility in the past 3 months.
HDP1 Share Price and Events
7 Day Returns
29.1%
DB:HDP1
2%
DE Biotechs
0.6%
DE Market
1 Year Returns
233.6%
DB:HDP1
-0.8%
DE Biotechs
-12.4%
DE Market
HDP1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Arrowhead Pharmaceuticals (HDP1) 29.1% 17.2% 34.2% 233.6% 350.7% -7.8%
DE Biotechs 2% -4.7% -1.5% -0.8% 84.7% 10.8%
DE Market 0.6% 2% -1.8% -12.4% 9.8% 4%
1 Year Return vs Industry and Market
  • HDP1 outperformed the Biotechs industry which returned -0.8% over the past year.
  • HDP1 outperformed the Market in Germany which returned -12.4% over the past year.
Price Volatility
HDP1
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Arrowhead Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Arrowhead Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €15.21.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Arrowhead Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Arrowhead Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:HDP1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.33
NasdaqGS:ARWR Share Price ** NasdaqGS (2019-02-14) in USD $17.61
Europe Biotechs Industry PE Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 28.12x
Germany Market PE Ratio Median Figure of 420 Publicly-Listed Companies 17.9x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Arrowhead Pharmaceuticals.

DB:HDP1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ARWR Share Price ÷ EPS (both in USD)

= 17.61 ÷ -0.33

-52.87x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Arrowhead Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Arrowhead Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Arrowhead Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:HDP1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -52.87x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
12%per year
Europe Biotechs Industry PEG Ratio Median Figure of 21 Publicly-Listed Biotechs Companies 1.45x
Germany Market PEG Ratio Median Figure of 276 Publicly-Listed Companies 1.43x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Arrowhead Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Arrowhead Pharmaceuticals's assets?
Raw Data
DB:HDP1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.86
NasdaqGS:ARWR Share Price * NasdaqGS (2019-02-14) in USD $17.61
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 2.43x
Germany Market PB Ratio Median Figure of 566 Publicly-Listed Companies 1.76x
DB:HDP1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ARWR Share Price ÷ Book Value per Share (both in USD)

= 17.61 ÷ 1.86

9.48x

* Primary Listing of Arrowhead Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Arrowhead Pharmaceuticals is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Arrowhead Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Arrowhead Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Arrowhead Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Arrowhead Pharmaceuticals expected to grow at an attractive rate?
  • Arrowhead Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Arrowhead Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Arrowhead Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:HDP1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:HDP1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 12%
DB:HDP1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 12%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 32.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 28.7%
Germany Market Earnings Growth Rate Market Cap Weighted Average 9.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:HDP1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:HDP1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-09-30 322 201 1
2022-09-30 283 165 1
2021-09-30 78 -50 2
2020-09-30 76 -44 -18 6
2019-09-30 195 159 99 7
DB:HDP1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 47 136 -29
2018-09-30 16 -47 -54
2018-06-30 14 -54 -54
2018-03-31 22 -50 -44
2017-12-31 31 -49 -35
2017-09-30 31 -24 -34
2017-06-30 23 -25 -46
2017-03-31 13 -33 -60
2016-12-31 4 -33 -75
2016-09-30 0 -64 -82
2016-06-30 0 -66 -84
2016-03-31 0 -61 -81

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Arrowhead Pharmaceuticals's earnings are expected to grow by 12% yearly, however this is not considered high growth (20% yearly).
  • Arrowhead Pharmaceuticals's revenue is expected to grow by 12% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:HDP1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Arrowhead Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:HDP1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-09-30 1.89 1.89 1.89 1.00
2022-09-30 1.57 1.57 1.57 1.00
2021-09-30 -0.56 0.15 -1.26 2.00
2020-09-30 -0.24 0.26 -0.78 6.00
2019-09-30 1.04 1.49 0.39 7.00
DB:HDP1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.33
2018-09-30 -0.65
2018-06-30 -0.68
2018-03-31 -0.58
2017-12-31 -0.47
2017-09-30 -0.47
2017-06-30 -0.64
2017-03-31 -0.88
2016-12-31 -1.16
2016-09-30 -1.34
2016-06-30 -1.41
2016-03-31 -1.36

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Arrowhead Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Arrowhead Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Arrowhead Pharmaceuticals has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Arrowhead Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Arrowhead Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Arrowhead Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Arrowhead Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Arrowhead Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Arrowhead Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Arrowhead Pharmaceuticals Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:HDP1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 47.29 -29.21 20.84 57.63
2018-09-30 16.14 -54.45 19.11 52.97
2018-06-30 13.60 -54.42 34.96 28.96
2018-03-31 22.22 -44.33 34.30 28.04
2017-12-31 30.55 -35.49 13.35 54.30
2017-09-30 31.41 -34.38 17.50 50.90
2017-06-30 22.73 -45.87 24.88 49.36
2017-03-31 13.42 -59.77 31.53 46.21
2016-12-31 4.48 -74.54 42.22 39.73
2016-09-30 0.16 -81.72 24.91 60.80
2016-06-30 0.17 -84.24 41.06 39.13
2016-03-31 0.26 -80.76 39.60 37.40
2015-12-31 0.26 -88.63 36.34 39.24
2015-09-30 0.38 -91.94 35.24 46.74
2015-06-30 0.38 -89.63 32.15 44.89
2015-03-31 0.30 -85.32 30.35 43.78
2014-12-31 0.30 -70.58 28.42 37.49
2014-09-30 0.18 -58.63 24.78 22.78
2014-06-30 0.18 -49.89 18.86 17.46
2014-03-31 0.18 -44.34 15.58 12.94
2013-12-31 0.18 -37.16 12.63 9.90
2013-09-30 0.29 -31.14 12.06 8.34
2013-06-30 0.29 -22.76 11.65 7.38
2013-03-31 0.29 -24.68 13.94 6.85
2012-12-31 0.28 -23.25 14.26 6.14
2012-09-30 0.15 -21.13 14.46 5.03
2012-06-30 0.10 -18.59 13.51 1.85
2012-03-31 0.06 -12.35 9.64 1.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Arrowhead Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Arrowhead Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Arrowhead Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Arrowhead Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Arrowhead Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Arrowhead Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Arrowhead Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Arrowhead Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Arrowhead Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Arrowhead Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Arrowhead Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Arrowhead Pharmaceuticals Company Filings, last reported 1 month ago.

DB:HDP1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 171.50 0.00 243.75
2018-09-30 95.24 2.33 76.53
2018-06-30 101.76 2.38 60.48
2018-03-31 113.72 2.43 91.54
2017-12-31 70.20 2.48 50.70
2017-09-30 80.87 2.53 65.61
2017-06-30 89.54 2.58 75.14
2017-03-31 93.34 2.63 86.63
2016-12-31 97.21 2.68 102.11
2016-09-30 95.02 2.73 85.37
2016-06-30 59.43 3.32 44.65
2016-03-31 73.93 0.65 61.46
2015-12-31 92.37 0.70 76.60
2015-09-30 109.62 0.76 98.75
2015-06-30 130.74 0.81 110.53
2015-03-31 144.20 0.87 116.01
2014-12-31 145.71 0.92 127.52
2014-09-30 165.99 1.02 154.16
2014-06-30 185.81 1.08 162.18
2014-03-31 189.54 2.13 160.65
2013-12-31 80.91 2.28 75.63
2013-09-30 25.73 2.30 28.14
2013-06-30 33.31 2.31 33.08
2013-03-31 3.76 2.32 3.31
2012-12-31 7.60 2.43 2.99
2012-09-30 8.81 2.44 3.48
2012-06-30 8.45 2.34 2.39
2012-03-31 11.57 2.35 3.67
  • Arrowhead Pharmaceuticals has no debt.
  • Arrowhead Pharmaceuticals has no debt compared to 5 years ago when it was 2.8%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Arrowhead Pharmaceuticals has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Arrowhead Pharmaceuticals has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -51.4% per year.
X
Financial health checks
We assess Arrowhead Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Arrowhead Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Arrowhead Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Arrowhead Pharmaceuticals dividends.
If you bought €2,000 of Arrowhead Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Arrowhead Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Arrowhead Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:HDP1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 330 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.5%
Germany Top 25% Dividend Yield 75th Percentile 4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:HDP1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-09-30
2022-09-30
2021-09-30
2020-09-30
2019-09-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Arrowhead Pharmaceuticals has not reported any payouts.
  • Unable to verify if Arrowhead Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Arrowhead Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Arrowhead Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Arrowhead Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Arrowhead Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Arrowhead Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Arrowhead Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Anzalone
COMPENSATION $1,871,214
AGE 49
TENURE AS CEO 11.2 years
CEO Bio

Dr. Christopher R. Anzalone, also known as Chris, Ph.D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer of Calando Pharmaceuticals, Inc. Dr. Anzalone was the Founder Benet Group, LLC and served as its Chief Executive Officer since 1999 until 2003. He serves as Chief Executive Officer of Tego, Leonardo and Ablaris Therapeutics. He focuses on creating and building new nano-biotechnology companies from university-generated science. He has a wealth of experience in nanotechnology, biotechnology, company-building, biomedical research, investment banking, financial services and venture capital. He is the founding Chief Executive Officer of Nanotope Inc. Dr. Anzalone is also the founding Chief Executive Officer of Leonardo Biosystems. Prior to Benet, Dr. Anzalone was a Partner at Galway Partners, LLC in Washington DC. He joined the firm in 1998 and was involved in sourcing, developing and structuring new business ventures. While at Galway, he was the founding Chief Executive Officer of NanoInk, Inc. He also served as an acting Chief Executive Officer and Chairman for two years at NanoInk. He serves as Chairman and Director of Calando Pharmaceuticals, Inc. He has been a Director of Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He served as a Director of NanoInk, Inc. Before joining Galway, Dr. Anzalone was a National Institutes of Health Fellow at the Smithsonian Institution's Conservation and Research Center Division of the National Zoological Park specializing in embryology and altered germ cell DNA-protein interactions. His research at the Smithsonian and prior to that at the University of California Los Angeles was funded for six years by the NIH. He was an active scientist with publications in the areas of Molecular Biology, Endocrine Physiology, Reproductive Biology and Conservation Biology. Dr. Anzalone is the author of numerous peer-reviewed research publications and has served as a reviewer for international scientific journals. He is the recipient of a number of professional and academic honors and has been a featured speaker at conferences, symposia and research institutions. Dr. Anzalone holds a Ph.D. and an M.A. in Biology from UCLA and a B.A. Government from Lawrence University.

CEO Compensation
  • Chris's compensation has increased whilst company is loss making.
  • Chris's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Arrowhead Pharmaceuticals management team in years:

9
Average Tenure
53
Average Age
  • The average tenure for the Arrowhead Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Chris Anzalone

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
49
TENURE
11.2 yrs

Ken Myszkowski

TITLE
Chief Financial Officer
COMPENSATION
$725K
AGE
52
TENURE
9 yrs

Bruce Given

TITLE
Chief Operating Officer
COMPENSATION
$1M
AGE
64
TENURE
7.3 yrs

Patrick O'Brien

TITLE
General Counsel
COMPENSATION
$805K
AGE
54
TENURE
4.2 yrs

Mark Davis

TITLE
Founder and Founder & Director of Insert Therapeutics Inc & Calando

Jane Davidson

TITLE
Head of Human Resources & Administration

Vincent Anzalone

TITLE
Head of Investor Relations & VP

Howard Lovy

TITLE
Director of Communications
TENURE
13.5 yrs

James Hamilton

TITLE
Head of Clinical Development & VP

Susan Boynton

TITLE
Head of Regulatory Affairs
Board of Directors Tenure

Average tenure and age of the Arrowhead Pharmaceuticals board of directors in years:

8.5
Average Tenure
59
Average Age
  • The tenure for the Arrowhead Pharmaceuticals board of directors is about average.
Board of Directors

Doug Given

TITLE
Chairman of the Board
COMPENSATION
$202K
AGE
66

Chris Anzalone

TITLE
CEO, President & Director
COMPENSATION
$2M
AGE
49
TENURE
11.2 yrs

Mark Davis

TITLE
Founder and Founder & Director of Insert Therapeutics Inc & Calando

Mike Perry

TITLE
Independent Lead Director
COMPENSATION
$191K
AGE
59

Robert Gish

TITLE
Chairman of Hepatitis B Clinical Advisory Board

Will Waddill

TITLE
Independent Director
AGE
61
TENURE
1.1 yrs

Mauro Ferrari

TITLE
Independent Director
COMPENSATION
$129K
AGE
59
TENURE
8.5 yrs

Stephen Locarnini

TITLE
Member of Hepatitis B Clinical Advisory Board

Ching-Lung Lai

TITLE
Member of Hepatitis B Clinical Advisory Board

Johnson Lau

TITLE
Member of Hepatitis B Clinical Advisory Board
Who owns this company?
Recent Insider Trading
  • Arrowhead Pharmaceuticals insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
11. Jan 19 Sell William Waddill Individual 11. Jan 19 11. Jan 19 -8,500 €12.88 €-109,438
X
Management checks
We assess Arrowhead Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Arrowhead Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Map
Description

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma. It is also involved in the development of ARO-HBV, a third-generation subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; AMG 890 to reduce production of apolipoprotein A; and ARO-AMG1 for treating undisclosed genetically-validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and Janssen Pharmaceuticals, Inc. to develop RNAi therapeutics. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Details
Name: Arrowhead Pharmaceuticals, Inc.
HDP1
Exchange: DB
Founded: 1989
$1,471,526,073
94,207,393
Website: http://arrowheadpharma.com
Address: Arrowhead Pharmaceuticals, Inc.
225 South Lake Avenue,
Suite 1050,
Pasadena,
California, 91101,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ARWR Common Stock Nasdaq Global Select US USD 13. Jan 2004
DB HDP1 Common Stock Deutsche Boerse AG DE EUR 13. Jan 2004
LSE 0HI3 Common Stock London Stock Exchange GB USD 13. Jan 2004
Number of employees
Current staff
Staff numbers
116
Arrowhead Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/15 20:34
End of day share price update: 2019/02/14 00:00
Last estimates confirmation: 2019/02/12
Last earnings filing: 2019/02/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.